ClinicalTrials.gov
ClinicalTrials.gov Menu

Copeptin in Differentiation of Polyuria and Polydipsia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01056887
Recruitment Status : Completed
First Posted : January 26, 2010
Last Update Posted : April 25, 2011
Sponsor:
Collaborator:
Dr. Carson Liu Med Corp.
Information provided by:
University of Wuerzburg

Brief Summary:

The differential diagnosis of patients with polyuria/ polydipsia is often complex, but important for the therapeutic strategy.

Challenging is in particular the clinical differentiation between patients with a partial Diabetes insipidus centralis and patients with primary polydipsia as underlying disease, because both groups are associated with similar urinary osmolalities.

The determination of plasma arginine vasopressin is unusual in this context, since measurement of AVP is not reliably.

C-terminal ProVasopressin (copeptin) is secreted stoichiometrically with AVP from the neurohypophysis, but has a longer half life in the circulation, and is thus easier to measure.

Therefore, the investigators will analyze in that study the diagnostic utility of plasma copeptin in the differential diagnosis of polyuria and polydipsia.


Condition or disease
Polyuria Polydipsia

Study Type : Observational
Estimated Enrollment : 50 participants
Observational Model: Cohort
Time Perspective: Prospective
Study Start Date : March 2008
Actual Primary Completion Date : November 2010
Actual Study Completion Date : November 2010


Group/Cohort
Primary Polydip, D. insipidus




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Healthy probands Patients with diabetes insipdus centralis totalis/ partials Patients with diabetes insipidus renalis Patients with primary polydipsia
Criteria

Inclusion Criteria:

  • Patients with polydipsia/ polyuria, with indication for performing a deprivation test
  • > 18 years

Exclusion Criteria:

  • dDAVP during the last 14d
  • pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01056887


Locations
Germany
Univ Hospital Wuerzburg
Wuerzburg, Bavaria, Germany, 97080
Sponsors and Collaborators
University of Wuerzburg
Dr. Carson Liu Med Corp.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Prof. Dr. med. Bruno Allolio, FDAAA
ClinicalTrials.gov Identifier: NCT01056887     History of Changes
Other Study ID Numbers: 17121979
33/07
First Posted: January 26, 2010    Key Record Dates
Last Update Posted: April 25, 2011
Last Verified: November 2010

Keywords provided by University of Wuerzburg:
diabetes insipidus
primary polydipsia
copeptin
Utility of plasma copeptin in differential diagnosis of polyuria/ polydipsia while performing a traditional deprivation test

Additional relevant MeSH terms:
Polyuria
Polydipsia
Urination Disorders
Urologic Diseases
Urological Manifestations
Signs and Symptoms
Pathologic Processes
Arginine Vasopressin
Hemostatics
Coagulants
Vasoconstrictor Agents
Antidiuretic Agents
Natriuretic Agents
Physiological Effects of Drugs